Lung Cancer >International Congress for Lung Cancer and Head & Neck Cancer - Philadelphia, PA >Agenda
Agenda
Saturday - November 5, 2011
Philadelphia, PA
Agenda
| 7:55AM | Welcome and Introductions | Chandra P. Belani, MD |
| 8:00 AM | Personalizing Therapy for Advanced Non−Small-Cell Lung Cancer: Role of Histology | Corey Langer, MD |
| 8:25 AM | Adjuvant Therapy and Multi-Modality Therapy for Non−Small-Cell Lung Cancer: Consensus and Controversies | Rodney Landreneau, MD |
| 8:50 AM | Current Clinical Practice and Ongoing Clinical Trials of Non−Small-Cell Lung Cancer in Europe | Mary O'Brien, MD |
| 9:15 AM | Interactive Case Discussion | Corey Langer, MD/Rodney Landreneau, MD/ Mary O'Brien, MD |
| 9:30 AM | Maintenance Therapy for Patients with Non−Small-Cell Lung Cancer: Switch Therapy | Chandra P. Belani, MD |
| 9:50 AM | Maintenance Therapy for Patients with Non−Small-Cell Lung Cancer: Continuation Therapy | Hossein Borghaei, DO, MS |
| 10:10 AM | BREAK | |
| 10:20 AM | Bevacizumab in Treatment of all Patients with Non−Small-Cell Lung Cancer - PRO | Chandra P. Belani, MD |
| 10:40 AM | Bevacizumab in Treatment of for all Patients with Non− Small-Cell Lung Cancer - CON | Julie Brahmer, MD |
| 11:00 AM | Interactive Case Discussion | Chandra P. Belani, MD/ Hossein Borghaei,DO, MS/Julie Brahmer, MD |
| 11:15 AM | EGFR inhibitors in the First-line, Second line and Maintenance Setting: Proper Selection of Patients and Resistance to EGFR TKIs | Roman Perez-soler, MD |
| 11:40 AM | Combined Modality Therapy in the Treatment of Patients with Stage III Non−Small-Cell Lung Cancer and Head & Neck Cancer | Walter Curran, MD |
| 12:05 PM | LUNCH | |
| 12:50 PM | Current Strategies and Integration of Novel Agents in the Treatment of Head & Neck Cancer | Corey Langer, MD |
| 1:15 PM | Current Strategies and Integration of Novel Agents in the Treatment of Patients with Limited and Extensive Small-Cell Lung Cancer | Afshin Dowlati, MD |
| 1:40 PM | Interactive Case Discussion | Roman Perez-soler, MD/ Walter Curran. MD/Corey Langer, MD/Afshin Dowlati, MD |
| 1:55 PM | Symptom Control and Management of Toxicities Associated with Chemotherapy and Targeted Agents in Patients with Lung Cancer | TBD |
| 2:20 PM | Supportive Cancer Therapy Issues in the Management of Lung Cancer | Richard Gralla, MD |
| 2:45 PM | Interactive Case Discussion | TBD/Richard Gralla, MD |
| 3:00 PM | HDAC Inhibitors, Talactoferrin/STA 9090, other HSP 90 inhibitors and Farletuzumab | Ahshin Dowlati, MD |
| 3:25 PM | C MET Inhibitors - Met MAb and ARQ197, EGFL-7, Linifanib and Hedge-Hog Inhibitors | Roman Perez-soler, MD |
| 3:50 PM | Interactive Case Discussion | |
| 4:00 PM | Closing Remarks and Adjourn | Chandra P. Belani, MD |